US Stock MarketDetailed Quotes
FBLG FibroBiologics
- 3.580
- +0.330+10.15%
Close Nov 6 16:00 ET
- 3.700
- +0.120+3.35%
Pre 08:00 ET
126.23MMarket Cap-6016P/E (TTM)
3.600High3.210Low299.14KVolume3.360Open3.250Pre Close1.03MTurnover1.18%Turnover RatioLossP/E (Static)35.26MShares55.00052wk High-52.65P/B90.63MFloat Cap1.07852wk Low--Dividend TTM25.32MShs Float55.000Historical High--Div YieldTTM12.00%Amplitude1.078Historical Low3.446Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
FibroBiologics Stock Forum
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG) reported promising results from its artificial thymus organoid program. The technology demonstrated that fibroblasts and thymus-derived cell organoids can maintain functionality for over 50 days after transplantation, showing vascularization and generating diverse mature T cells in animal models. The organoids produced fully mature T cells with various diff...
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
According to the EMH, it is impossible to consistently outperform the market by employing strategies such as technical or fundamental analysis. The hypothesis argues that since all relevant information is already reflected in stock prices, it is not possible to gain an advantage and generate abnormal returns through stock picking or market timing. ...
$Primega Group (PGHL.US)$
$FibroBiologics (FBLG.US)$
$OrangeKloud Technology (ORKT.US)$
Last month was a good one.
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
FibroBiologics (Nasdaq: FBLG) has filed a patent application for an adhesive bandage using fibroblast cell-based technology for wound healing. This innovative approach aims to leverage the healing properties of fibroblasts in a stable, room-temperature bandage suitable for post-surgical and retail use. The company, which focuses on...
The rest of stock continue to fall on a friday
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, has developed a novel artificial thymus organoid capable of restoring immune function in severe combined immunodeficiency (SCID) mouse models. This organoid is made from fibroblasts and thymus-derived cells and can produce mature and diverse T cells, including CD4, CD8, and regulatory T cells. The comp...
No comment yet